Jazz Lifts 2026 Revenue Outlook To $4.775 Billion–$4.85 Billion Despite $754 Million Actio Charge

Record third-quarter revenue of $1,243.0 million met a $483.4 million net loss driven by acquired research expense.

Share
Jazz Lifts 2026 Revenue Outlook To $4.775 Billion–$4.85 Billion Despite $754 Million Actio Charge

Jazz Pharmaceuticals, the rare-disease drugmaker behind Xywav and Epidiolex, raised its 2026 revenue guidance to $4.775 billion to $4.85 billion after record third-quarter sales, even as a $754 million charge for its Actio Biosciences deal produced a quarterly loss. The company reported the results Monday.

Record sales, a $483.4 million loss

Total revenues reached $1,243.0 million, up 10% from $1,126.1 million a year earlier. Jazz called it a record quarter, with higher sales of Xywav, Zepzelca and Ziihera, plus Modeyso, which was not on the market for the full year-earlier quarter.

The bottom line went the other way: a net loss of $483.4 million, or $7.48 per share, against net income of $251.4 million a year earlier. Acquired in-process research and development expense of $754 million, the value assigned to ABS-1230 in the Actio deal, cost $11.32 per share on a standard-accounting basis.

On an adjusted basis the quarter showed a loss of $3.88 per share versus earnings of $8.13 a year earlier. The company said the charge hit adjusted results by $11.03 per share. For the first nine months, adjusted earnings were $8.23 per share, up from $1.63.

The new guidance compares with $4.6 billion to $4.75 billion given on August 3. The standard-accounting effective tax rate range moved to 20% to 30% from 0% to 10%, which the company tied to the Actio charge.

Xywav and oncology carry the quarter

Jazz develops and sells medicines for rare diseases across sleep disorders, epilepsy and cancer. Xywav net sales rose 12% to $483 million, with about 425 net patient adds and roughly 17,550 active patients exiting the quarter.

Oncology revenue rose to $387.1 million from $287.8 million. Zepzelca sales climbed 32% to $104 million and Modeyso reached $61 million. Ziihera sales were $21 million after its August 25 FDA approval for first-line HER2-positive gastroesophageal adenocarcinoma.

Epidiolex and Epidyolex sales slipped 2% to $295 million, which the company attributed to lower U.S. gross-to-net deductions a year earlier and wholesaler buying patterns. Xyrem sales fell to $31.2 million from $35.7 million.

Cash, notes and the Actio pipeline

In the third quarter Jazz privately placed $1.25 billion of 1.875% exchangeable senior notes due 2032 and repurchased $225 million of shares. In October its board approved a new buyback of up to $500 million. At September 30, cash and investments were $2.9 billion against $5.6 billion of long-term debt principal.

Jazz closed the Actio deal in September. ABS-1230 is a potential first-in-class therapy for KCNT1-related epilepsy, and the company expects to present initial patient data at a medical meeting in the fourth quarter.

The FDA's target action date for Jazz's oral cannabidiol capsule application is April 16, 2027.

Sources

More on Jazz Pharmaceuticals

All Jazz Pharmaceuticals (JAZZ) coverage →